Loading...

Deciphera Pharmaceuticals

DB:D05
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
D05
DB
$968M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
D05 Share Price and Events
7 Day Returns
6.6%
DB:D05
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
13.6%
DB:D05
-10.6%
DE Biotechs
-6.2%
DE Market
D05 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Deciphera Pharmaceuticals (D05) 6.6% 0.1% -7.9% 13.6% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • D05 outperformed the Biotechs industry which returned -10.6% over the past year.
  • D05 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

D05 Value

 Is Deciphera Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Deciphera Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €21.365.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Deciphera Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Deciphera Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:D05 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.82
NasdaqGS:DCPH Share Price ** NasdaqGS (2019-04-23) in USD $25.35
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Deciphera Pharmaceuticals.

DB:D05 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DCPH Share Price ÷ EPS (both in USD)

= 25.35 ÷ -2.82

-8.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deciphera Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Deciphera Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Deciphera Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:D05 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
10.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Deciphera Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Deciphera Pharmaceuticals's assets?
Raw Data
DB:D05 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.43
NasdaqGS:DCPH Share Price * NasdaqGS (2019-04-23) in USD $25.35
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:D05 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DCPH Share Price ÷ Book Value per Share (both in USD)

= 25.35 ÷ 7.43

3.41x

* Primary Listing of Deciphera Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deciphera Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Deciphera Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Deciphera Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

D05 Future Performance

 How is Deciphera Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Deciphera Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Deciphera Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Deciphera Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Deciphera Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:D05 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:D05 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 10.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:D05 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:D05 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 255 14 -3 3
2022-12-31 129 -91 -89 3
2021-12-31 43 -53 -155 3
2020-12-31 21 -150 -160 6
2019-12-31 0 -99 -139 7
DB:D05 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -87 -100
2018-09-30 -73 -87
2018-06-30 -57 -75
2018-03-31 -46 -64
2017-12-31 -37 -50
2017-09-30 -31 -39
2017-06-30 -28 -33
2017-03-31 -25 -28
2016-12-31 -23 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Deciphera Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Deciphera Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:D05 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Deciphera Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:D05 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.05 2.73 -2.09 3.00
2022-12-31 -1.61 -0.20 -2.64 3.00
2021-12-31 -2.93 -2.33 -3.42 3.00
2020-12-31 -3.63 -2.78 -4.46 8.00
2019-12-31 -3.29 -1.51 -4.17 8.00
DB:D05 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.82
2018-09-30 -2.57
2018-06-30 -2.73
2018-03-31 -2.90
2017-12-31 -2.99
2017-09-30 -1.19
2017-06-30 -2.84
2017-03-31 -2.43
2016-12-31 -2.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Deciphera Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Deciphera Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Deciphera Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

D05 Past Performance

  How has Deciphera Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Deciphera Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Deciphera Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Deciphera Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Deciphera Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Deciphera Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Deciphera Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:D05 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -99.85 21.21 82.89
2018-09-30 -87.47 19.42 71.19
2018-06-30 -75.07 16.59 60.31
2018-03-31 -64.01 14.38 50.78
2017-12-31 -50.28 11.42 39.51
2017-09-30 -38.93 8.74 30.39
2017-06-30 -32.99 7.66 25.36
2017-03-31 -28.30 6.73 21.51
2016-12-31 -25.94 5.68 20.16
2015-12-31 -19.82 5.14 12.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Deciphera Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Deciphera Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Deciphera Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Deciphera Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Deciphera Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

D05 Health

 How is Deciphera Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Deciphera Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Deciphera Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Deciphera Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Deciphera Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Deciphera Pharmaceuticals Company Filings, last reported 3 months ago.

DB:D05 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 279.98 12.64 293.76
2018-09-30 309.37 18.88 320.88
2018-06-30 331.10 18.28 346.53
2018-03-31 164.59 1.44 179.87
2017-12-31 183.97 1.48 196.75
2017-09-30 76.43 1.53 82.15
2017-06-30 87.45 1.58 93.99
2017-03-31 45.61 1.62 49.96
2016-12-31 52.91 1.67 57.46
2015-12-31 22.06 1.87 25.78
  • Deciphera Pharmaceuticals's level of debt (4.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Deciphera Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Deciphera Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Deciphera Pharmaceuticals has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 56.8% each year.
X
Financial health checks
We assess Deciphera Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Deciphera Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

D05 Dividends

 What is Deciphera Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Deciphera Pharmaceuticals dividends.
If you bought €2,000 of Deciphera Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Deciphera Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Deciphera Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:D05 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:D05 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Deciphera Pharmaceuticals has not reported any payouts.
  • Unable to verify if Deciphera Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Deciphera Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Deciphera Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Deciphera Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Deciphera Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Deciphera Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

D05 Management

 What is the CEO of Deciphera Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Hoerter
AGE 47
TENURE AS CEO 0.1 years
CEO Bio

Mr. Steven L. Hoerter, also known as Steve, serves as President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since March 18, 2019. He serves as Director at Constellation Pharmaceuticals, Inc. since September 04, 2018. He served as the Chief Commercial Officer at Agios Pharmaceuticals, Inc since February 16, 2016 until March 15, 2019. Mr. Hoerter has more than 20 years of global pharmaceutical and biotechnology experience. Mr. Hoerter served as Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. since March 2015 until January 25, 2016 and served as its Senior Vice President of Commercial Operations from August 2011 to March 2015. Mr. Hoerter built and led the global commercial organization that developed go-to-market strategies for two oncology therapies. From 2010 to 2011, he served as General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech's BioOncology business as Senior Director of Pipeline Development and Commercial Operations. Prior to, he held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe and Africa (11 year career). He has been an Independent Director of Deciphera Pharmaceuticals, Inc. since May 17, 2018. He served as Director of Ignyta, Inc. since December 8, 2016 until February 8, 2018. Mr. Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and an M.S. in Management from Purdue University.

CEO Compensation
  • Insufficient data for Steve to compare compensation growth.
  • Insufficient data for Steve to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Deciphera Pharmaceuticals management team in years:

0.8
Average Tenure
50.5
Average Age
  • The average tenure for the Deciphera Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Daniel Flynn

TITLE
Executive VP
COMPENSATION
$1M
AGE
63
TENURE
16.3 yrs

Chris Morl

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
59
TENURE
2.5 yrs

Steve Hoerter

TITLE
President
AGE
47
TENURE
0.1 yrs

Tucker Kelly

TITLE
Executive VP
AGE
47
TENURE
4.2 yrs

Stephen Ruddy

TITLE
Chief Technical Officer
AGE
54
TENURE
0.9 yrs

Jeff Held

TITLE
General Counsel
TENURE
0.1 yrs

Peter Lasky

TITLE
Vice President of Human Resources
TENURE
0.1 yrs

Dan Martin

TITLE
Chief Commercial Officer
AGE
43
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Deciphera Pharmaceuticals board of directors in years:

3.8
Average Tenure
56.5
Average Age
  • The tenure for the Deciphera Pharmaceuticals board of directors is about average.
Board of Directors

Jim Bristol

TITLE
Chairman
COMPENSATION
$352K
AGE
71
TENURE
4.2 yrs

Steve Hoerter

TITLE
President
AGE
47
TENURE
0.9 yrs

Edward Benz

TITLE
Director
COMPENSATION
$81K
AGE
72
TENURE
2.5 yrs

Patricia Allen

TITLE
Director
COMPENSATION
$90K
AGE
56
TENURE
2.6 yrs

Filip Janku

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

F. Hodi

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

Jean-Yves Blay

TITLE
Member of Scientific Advisory Board
AGE
56
TENURE
3.8 yrs

Mike Ross

TITLE
Director
COMPENSATION
$747K
AGE
69
TENURE
3.3 yrs

John Martin

TITLE
Director
COMPENSATION
$736K
AGE
57
TENURE
4.2 yrs

Dennis Walsh

TITLE
Director
COMPENSATION
$738K
AGE
50
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Deciphera Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Deciphera Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

D05 News

Simply Wall St News

D05 Company Info

Description

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company’s lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Details
Name: Deciphera Pharmaceuticals, Inc.
D05
Exchange: DB
Founded: 2003
$863,925,718
38,189,052
Website: http://www.deciphera.com
Address: Deciphera Pharmaceuticals, Inc.
500 Totten Pond Road,
6th Floor,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DCPH Common Stock Nasdaq Global Select US USD 28. Sep 2017
DB D05 Common Stock Deutsche Boerse AG DE EUR 28. Sep 2017
Number of employees
Current staff
Staff numbers
113
Deciphera Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:26
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.